Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.
Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. Cancer. 2013 Aug 15; 119(16):3043-51.